<div class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<em>n</em>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prior Lines of Therapy</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Prior CDK4/6i</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PFS</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Response Rate</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<strong>Alpelisib fulvestrant</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Phase II, BYLieve trial, Cohort A</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have had CDK4/6i</div></li><li><div>Patients had not received more than 3 lines of therapy</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.3 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORR 17%<br> CBR 55%</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B21-cancers-15-01855" rid="B21-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">21</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Phase II, BYLieve trial, Cohort C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Patients had not received more than 3 lines of therapy</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
84%
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
5.6 months
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
ORR 28%<br> CBR 43%
</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B22-cancers-15-01855" rid="B22-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">22</a>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<strong>Fulvestrant</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, Phase III <br> EMERALD trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">165</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have had CDK4/6i</div></li><li><div>≤2 prior lines of endocrine therapy</div></li><li><div>≤1 line of chemotherapy</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.9 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6-month PFS rate 23%<br> 12-month PFS rate 10%</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B23-cancers-15-01855" rid="B23-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">23</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, Phase II, <br> VERONICA trial</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have had CDK4/6i</div></li><li><div>≤2 prior lines of endocrine therapy</div></li><li><div>No prior cytotoxic chemotherapy</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.94 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBR 13.7%</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B24-cancers-15-01855" rid="B24-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">24</a>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<strong>Exemestane and everolimus</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have had CDK4/6i</div></li><li><div>Median 4 prior lines of therapy</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORR 17.1%<br> CBR 17.1%</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B25-cancers-15-01855" rid="B25-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">25</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have had CDK4/6i</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B26-cancers-15-01855" rid="B26-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">26</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have had CDK4/6i</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.7 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6-month PFS 18%</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B27-cancers-15-01855" rid="B27-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">27</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Prior therapy CDK4/6i</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.7 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B28-cancers-15-01855" rid="B28-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">28</a>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<strong>Sacituzumab govitecan</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, Phase I/II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Progressed on at least one prior endocrine therapy and chemotherapy</div></li><li><div>Subgroup analysis in pts with prior CDK4/6i</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORR 8%<br> CBR 12%</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B29-cancers-15-01855" rid="B29-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">29</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, Phase III <br> TROPiCs-02</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">272</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Progressed on a CDK4/6i and at least 2 chemotherapy agents including a taxane</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ORR at 21%<br> Improvement PFS compared to control: 1.5 months<br> Improvement in OS compared to control: 3.2 months</td><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">[<a href="#B30-cancers-15-01855" rid="B30-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">30</a>,<a href="#B31-cancers-15-01855" rid="B31-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">31</a>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<strong>Trastuzumab deruxtecan</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, Phase III <br> DESTINY-Breast04 *</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">331</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Must have received at least one line of chemotherapy</div></li><li><div>Must have received at least one line of endocrine therapy</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70.4%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.1 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBR: 71.2%,<br> ORR 52.6%<br> Improvement PFS compared to control: 4.7 months<br> Improvement in OS compared to control: 6.4 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B32-cancers-15-01855" rid="B32-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">32</a>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
<strong>Continuing CDK4/6i</strong>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective, Phase II <br> MAINTAIN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">120</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Progressed on CDK 4/6i and ET</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.29 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12-month PF rate 25%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B33-cancers-15-01855" rid="B33-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">33</a>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective Phase II PACE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">220</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<ul class="unordered" style="list-style-type:disc"><li><div>Progressed on CDK 4/6i and ET</div></li></ul>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.5%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fulvestrant: 4.8 months<br> Fulvestrant and palbociclib: 4.6 monthsFulvestrant, palbociclib, avelumab: 8.1 months</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CBR fulvestrant monotherapy: 29.1%<br> CBR fulvestrant, palbociclib: 32.4%<br> CBR fulvestrant, palbociclib, avelumab: 35.2%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<a href="#B34-cancers-15-01855" rid="B34-cancers-15-01855" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">34</a>]</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr></tbody></table></div>
